Peri-Implantitis

Researchers have identified genes that are overexpressed in peri-Implantitis, which may help in the diagnosis and treatment of the disease BUSAN, South Korea, Dec. 6, 2024 /PRNewswire/ -- The number of people receiving dental implants is increasing annually, as more individuals become aware of the advantages of replacing missing teeth. However, this rise has also been accompanied by a growing prevalence of PI. While treatment protocols for PI often mirror those designed for managing periodontitis, they have proven to be less effective. Additionally, PI has a higher chance of recurrence than periodontitis, posing greater challenges for management. Continue Reading Researchers have identified unique genetic markers of peri-Implantitis in a breakthrough that may improve the diagnosis and treatment of the chronic inflammatory disease that affects dental implants. Understanding the key differences in the pathophysiology of PI and periodontitis is essential for developing more specialized and effective treatments for PI. A significant breakthrough in efforts to identify these critical differences was made in the study, which uncovered a link between PI and activated fibroblasts. Activated fibroblasts are cells in the connective tissue that have started to proliferate abnormally. The study also identified three specific marker genes that were overexpressed in PI but not in periodontitis. This paper was made available online on 1st October 2024 and was published in Volume 151 of the Journal of Dentistry. "This study provides essential insights into the role of activated fibroblasts as a distinctive factor in the pathogenesis of peri-implantitis versus periodontitis. Although peri-implantitis and periodontitis share clinical similarities, they exhibit distinct biological pathways. This research identifies three key biomarkers—ACTA2, FAP, and PDGFRβ—that are markedly overexpressed in peri-implantitis. These biomarkers have the potential to facilitate differential diagnosis and contribute to the development of peri-implantitis-specific therapeutic approaches," explains Professor Yun Hak Kim, a lead researcher in the study. To understand the genetic, immunological and other physiological factors underlying PI and periodontitis, researchers collected gingival tissue from patients having both conditions. The samples were then processed to sequenced, and analyzed RNA obtained from the gingival tissue. The study identified the three genes that could serve as disease-specific biomarkers for PI, which can help clinicians diagnose the condition and make more informed decisions regarding treatment. Biomarker-based diagnostics could minimize misdiagnoses between peri-implantitis and periodontitis, thereby enhancing patient prognoses. By providing targeted treatment strategies for high-risk patients, particularly in peri-implantitis, this approach may contribute to reducing recurrence rates and improving overall therapeutic effectiveness. "These findings could drive significant advancements in clinical strategies for diagnosing and treating peri-implantitis," notes Professor Kim. While the treatment for periodontitis comprises of mechanical treatment to fix structural integrity of teeth and various antimicrobial treatments, PI treatment follows a similar protocol. Although controlling the disease with this approach is highly challenging. The differentially expressed genes identified in the study could be pivotal in developing new treatment approaches for PI that target its unique pathophysiology. "Over the next 5-10 years, this study's findings could serve as a fundamental basis for the development of highly specialized, targeted therapies addressing peri-implantitis, specifically focusing on its unique biological and immunological characteristics compared to periodontitis," concludes Professor Kim. This targeted approach could significantly contribute to extending the durability and success rates of dental implants, especially for patients at elevated risk of peri-implantitis due to underlying inflammatory conditions. Additionally, by elucidating the role of activated fibroblasts in peri-implantitis, this research offers valuable insights that could advance our understanding and treatment of other chronic inflammatory diseases with similar cellular mechanisms. Reference Title of original paper: Paired Transcriptional Analysis of Periodontitis and Peri-Implantitis within same host: a Pilot study Journal: Journal of Dentistry DOI: 10.1016/j.jdent.2024.105366 About Pusan National University Website: Media Contact: Goon-Soo Kim 82 51 510 7928 [email protected] SOURCE Pusan National University WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

PHILADELPHIA, April 23, 2024 /PRNewswire/ -- Every year, roughly 3 million Americans receive implants to replace lost teeth. While this technology has represented a leap of progress in dental care, over time, inflammation and gum disease ― nurtured by microbial biofilms, or plaque ― can affect the soft tissue and bone surrounding the implant and cause these tooth replacements to fail. An innovative new implant now on the horizon may one day address these issues, disrupting biofilms through its inherent antimicrobial and anti-inflammatory properties. The design of this next generation implant is the work of Dr. Geelsu Hwang at Penn Dental Medicine, who has a background in engineering that he brings to his research on biofilms and their role in oral health. "The lack of a good seal between the implant structure and the surrounding gum, compared to a natural tooth, means that the risk of disease around the implant is quite high," Hwang says. The new implant he and his collaborators are developing would interfere with biofilms and combat peri-implant infection in two ways: First, the crown, the artificial tooth atop the implant structure, will be suffused with nanoparticles made of a chemical compound that naturally wards off bacteria. Hwang and his team have been experimenting with the compound barium titanate (BTO). Second, the base of the crown will contain LEDs that deliver a regular dose of phototherapy to the surrounding gum tissue, giving off light at a wavelength that has antibacterial and anti-inflammatory properties. The LEDs will be powered by the piezoelectric material in the crown (like the BTO) that converts the motion of chewing or toothbrushing to electrical energy. Hwang notes that this platform could one day be integrated not only into dental implants, but into other applications, such as joint replacements, as well. In 2023, the National Institutes of Health awarded Hwang a five-year grant to further advance the implant development. The NIH funding will support tests of the new implant technology, using laboratory cultures of human gum tissue and, ultimately, test implants in mini pigs as preparation for human clinical trials. In related research, he is also studying a new piezoelectric dental composite material for fillings. The material would generate an enhanced electrical charge at the interface from the mechanical pressure of chewing, and this on its own would inhibit bacterial colonization of the composite surface. Contact: Beth Adams [email protected] SOURCE Penn Dental Medicine

SALT LAKE CITY--(BUSINESS WIRE)-- Spectrum Solutions®, saliva diagnostic biotech leader, today announced the official release of a new saliva diagnostic testing innovation, SimplyPERIO™. As advances in science continue to focus on the mouth-body connection and its direct link to systemic disease, SimplyPERIO™ fills a testing void by delivering more intelligent health measures with real clinical relevance using 16 oral targets from a single patient sample. Gum disease, also called periodontal disease, is one of the most undiagnosed and untreated diseases, but has some of the highest negative impacts on many bodily systems and functions. In addition, gum disease decreases a person’s ability to fight infection and inflammation. SimplyPERIO™ uses a proprietary molecular technology to test for and measure periodontal bacteria, caries, fungal and viral targets all for one affordable cost. Understanding treatment success is often influenced by host immunity and host response, this unique, highly sensitive and highly specific saliva test offers Providers the real opportunity to elevate patient care with the most complete oral health picture. “We are using science to make saliva diagnostics simple for both Patients and Providers. SimplyPERIO™ testing is not only pain-free it takes less than 30 seconds for a patient to collect their own sample,” said Dr. David Vigerust, PhD, Chief Science Officer at Spectrum Solutions. “In addition, our CAP accredited laboratory delivers Providers the independent, 3rd party results necessary for intelligent, data-supported patient conversations about stopping and even reversing their disease and systemic risks.” In the U.S., numbers illustrate that 80% of individuals over 35 have a form of gum disease. Gingivitis, periodontitis and peri-implantitis are all forms of gum disease. These numbers demonstrate that for the vast majority, there may be dangerous and damaging periodontal disease pathogens hiding that can't be identified with a perio-probe or visual exam during regular semi-annual cleanings. Gone unchecked, these harmful oral bacteria and toxins are allowed to sit and accumulate inside the mouth. From inside the mouth these microorganisms move freely to and through the bloodstream with far reaching and catastrophic effects on the heart, arteries, central nervous system and more. The SimplyPERIO™ patented blue buffer solution located inside the collection device’s cap stabilizes saliva samples at room temperature eliminating any special post-collection storage or shipping requirements. Easily deposit one at a time, supporting at-home patient testing for follow-up and treatment monitoring, or gather an entire day’s worth of in-office collections into the USPS postage-paid return box for mailing samples back to the lab for processing. ABOUT SPECTRUM SOLUTIONS® Headquartered in Salt Lake City, Utah, Spectrum Solutions is dedicated to empowering complete wellness and bridging the gap between science and innovative healthcare solutions. Our stand-alone and fully integrated test-to-treat solutions support molecular diagnostics and DTC testing applications, advancing product development and accelerating go-to-market applications. Our single-source, end-to-end capabilities include a CAP accredited molecular diagnostic laboratory, onsite compounding pharmacy, product development, manufacturing and fulfillment. SimplyTest® and Spectrum Solutions® are registered trademarks of Spectrum Solution, LLC. For more information, please visit spectrumsolution.com or simplytest.com.